Valuation dashboard for Surrozen, Inc. (SRZN) with P/E N/A, P/B -0.90, EV/EBITDA -0.22 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Analysis Summary
Trailing-twelve-month margins: gross margin 99.4%, operating margin -385.3%, net margin -28.9%.
At the current price of $16.93, SRZN has negative trailing earnings (P/E not meaningful) and an ROE of 187.62%. Market capitalisation stands at $127M.
Balance sheet quality for SRZN: current ratio of 9.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -0.90 |
| EV / EBITDA | -0.22 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $11.34 |
| vs Current Price | -33.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SRZN | Surrozen, Inc. | $127M | 187.6% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $16.93 |
| Market Cap | $127M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 187.62% |
| Return on Invested Capital | -40.84% |
| Return on Assets | -287.29% |
| Gross Margin | 99.44% |
| Operating Margin | -385.28% |
| Net Margin | -2885.33% |
Related companies: AGEN · ATOS · CGTX · GLSI · IMMX · IRD · SEER
Explore sector: Healthcare · Biotechnology
More sections of SRZN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks